This provides the first evidence that CTCF inactivation in conjunction with inactivation of CDH1 and/or ZFHX3 and/or other candidate genes on 16q contributes to the development of poorer prognosis tumour subtypes. This evidence concerns the gene CDH1 and neoplasm.